Previous Article | Next Article 
Molecular and Cellular Biology, April 2000, p. 2400-2410, Vol. 20, No. 7
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
SKIP, a CBF1-Associated Protein, Interacts with the
Ankyrin Repeat Domain of NotchIC To Facilitate NotchIC
Function
Sifang
Zhou,1
Masahiro
Fujimuro,1
James J.-D.
Hsieh,1
Lin
Chen,1
Alison
Miyamoto,2
Gerry
Weinmaster,2 and
S.
Diane
Hayward1,3,*
Department of Pharmacology and Molecular
Sciences1 and Oncology
Center,3 Johns Hopkins School of Medicine,
Baltimore, Maryland 21205, and Molecular Biology Institute,
University of California, Los Angeles, California
900952
Received 18 October 1999/Returned for modification 13 December
1999/Accepted 12 January 2000
 |
ABSTRACT |
Notch proteins are transmembrane receptors that mediate intercell
communication and direct individual cell fate decisions. The activated
intracellular form of Notch, NotchIC, translocates to the nucleus,
where it targets the DNA binding protein CBF1. CBF1 mediates
transcriptional repression through the recruitment of an SMRT-histone
deacetylase-containing corepressor complex. We have examined the
mechanism whereby NotchIC overcomes CBF1-mediated transcriptional
repression. We identified SKIP (Ski-interacting protein) as a CBF1
binding protein in a yeast two-hybrid screen. Both CBF1 and SKIP are
highly conserved evolutionarily, and the SKIP-CBF1 interaction is also
conserved in assays using the Caenorhabditis elegans and
Drosophila melanogaster SKIP homologs. Protein-protein interaction assays demonstrated interaction between SKIP and the corepressor SMRT. More surprisingly, SKIP also interacted with NotchIC.
The SMRT and NotchIC interactions were mutually exclusive. In
competition binding experiments SMRT displaced NotchIC from CBF1 and
from SKIP. Contact with SKIP is required for biological activity of
NotchIC. A mutation in the fourth ankyrin repeat that abolished Notch
signal transduction did not affect interaction with CBF1 but abolished
interaction with SKIP. Further, NotchIC was unable to block muscle cell
differentiation in myoblasts expressing antisense SKIP. The results
suggest a model in which NotchIC activates responsive promoters by
competing with the SMRT-corepressor complex for contacts on both CBF1
and SKIP.
 |
INTRODUCTION |
Notch is a cell surface receptor
that, when activated by ligand-expressing cells, influences a broad
spectrum of developmental processes (2). Notch signal
transduction regulates cell fate decisions by influencing
differentiation and proliferative responses to developmental cues. The
Notch signaling pathway is conserved among species, and the effects of
Drosophila melanogaster Notch and the Caenorhabditis
elegans homologs LIN-12 and GLP-1 on development have been the
subjects of extensive genetic analyses (18, 29). Notch
receptor proteins have characteristic structural features that include
an extracellular ligand binding domain comprising multiple tandemly
arrayed epidermal growth factor-like repeats followed by cysteine-rich
Notch/Lin-12 repeats and an intracellular domain containing six tandem
ankyrin repeats that are required for signal transduction. The
extracellular domain of Notch is cleaved by the furin protease in the
trans Golgi network as part of Notch maturation. The
resulting cleavage fragments remain associated and are found at the
surface as a heterodimeric receptor (6, 41). The Notch
ligands are transmembrane proteins of the DSL (Delta, Serrate, and
Lag-2) family that, like Notch, contain multiple epidermal growth
factor-like repeats in the extracellular domain (59).
The mechanism by which Notch signaling activates downstream target
genes has been the subject of controversy. The observation that the
intracellular domain of Notch, NotchIC, functions as a constitutively
activated Notch receptor (16, 31, 37, 56) formed the basis
for a model in which ligand binding induces proteolytic cleavage and
the release of NotchIC, which translocates to the nucleus. A
proteolytic site that releases NotchIC has been identified (53), and NotchIC cleavage has recently been linked to
presenilins (7, 12, 48, 57, 60).
Support for the nuclear translocation of NotchIC as a component of
signaling came from experiments with Drosophila using
chimeric constructions in which the Saccharomyces cerevisiae
Gal4 DNA binding domain was fused to full-length Notch just C-terminal
to the Notch transmembrane domain. In the presence of the Notch ligand
Delta, this chimeric Notch-Gal4 protein was able to activate a nuclear reporter containing Gal4 DNA binding sites (35, 55). An
important nuclear target of NotchIC is the CSL (CBF1 [also called
RBPJk and RBP2N], Su(H), and Lag-1) family of DNA binding proteins. Direct interaction between NotchIC and CSL proteins was demonstrated first for Drosophila (15) and subsequently for
mammalian cells (23, 26). Several genes containing CSL
protein binding sites in their promoters have been shown to be
responsive to Notch signaling. These include members of the mammalian
Hairy/Enhancer of split family of genes (24, 45), the
related Drosophila Enhancer of split genes (4,
36), and the C. elegans genes lin-12, glp-1, and lag-1 (9). The human CSL
protein CBF1 binds to the sequence GTGGGAA (39,
58) and functions as a transcriptional repressor (13,
22). CBF1-mediated repression involves destabilization of
transcription factor IID (TFIID)-TFIIA interactions (46) and
recruitment of a histone deacetylase (HDAC) corepressor complex to the
promoter (25, 28). CBF1 has been shown to interact with the
corepressor complex proteins SMRT and HDAC1 (28) and CIR,
SAP30, and HDAC2 (25). On binding to CBF1, NotchIC activates gene expression through a two-part mechanism, first, by overcoming CBF1-mediated repression and, second, by activating transcription through the presence of an endogenous activation domain (23, 32). Evidence that NotchIC abolishes CBF1 repression through displacement of the SMRT corepressor complex has been presented (28).
Disregulated expression of NotchIC not only affects cell fate responses
but also is associated with hematopoietic and epithelial malignancies.
Truncation of human Notch1 (TAN1) as a result of chromosomal
translocation was described for T-cell-lymphoblastic leukemia
(14); mice transplanted with bone marrow expressing activated Notch1IC developed T-cell neoplasms (47); Notch1
was the site of provirus insertional mutagenesis in T-cell tumors developing in a transgenic mouse model (17); T-cell
lymphomas were associated with transduction of Notch2IC by feline
leukemia virus (52), and the activated form of Notch4 causes
adenocarcinomas in transgenic mice (27). The transcriptional
reprogramming induced by NotchIC is a key aspect of Notch function in
development and tumorigenesis. To gain insight into the mechanism by
which NotchIC overcomes CBF1-mediated transcriptional repression, we
undertook a yeast two-hybrid screen to identify additional
CBF1-interacting proteins. This screen identified SKIP (Ski-interacting
protein), a human homolog of the Drosophila Bx42 protein
that was originally described as an interacting partner of the avian
retroviral oncogene v-Ski (11). c-Ski has recently been
found to be a component of the HDAC corepressor complex and to be
required for transcriptional repression by the Mad and thyroid hormone
receptor complexes (44). We present evidence that SKIP
interacts with the CBF1 corepressor complex and that SKIP has a role in
orchestrating the conversion of CBF1 from an SMRT-HDAC-tethered
transcriptional repressor to a NotchIC-tethered activation complex.
Analysis of the NotchIC interaction with SKIP provided insight into the
nature of the functional defect that results from mutation of the
fourth ankyrin repeat of Notch.
 |
MATERIALS AND METHODS |
Plasmids. (i) Yeast expression plasmids.
SKIP cDNA was
isolated from a B-cell library (Clontech) in a yeast two-hybrid screen
with CBF1 as the bait protein. The SKIP sequence is identical to that
of GenBank accession no. U51432 and 1 base different from that of
NCoA-62 (accession no. AF045184). The homolog C. elegans
SKIP (accession no. Z74045) was isolated from the C. elegans
clone YK117g2 obtained from The National Institute of Genetics,
Mishima, Japan. The D. melanogaster SKIP homolog (accession
no. X64536) cDNA was obtained from the Berkeley Drosophila Genome
Project. Lag-1 cDNA was obtained from J. Kimble (9). SNF1
and SNF4 controls were obtained commercially (Clontech). Proteins were
expressed in yeast as activation domain (ACT) fusions in the vector
pACTII or as DNA binding domain (DBD) fusions in the vector pAS1-CYH2.
Gal4ACT-EBNA2(252-476) (pYW163) and Gal4ACT-CBF1 (pJH346) plasmids
have been previously described, and Gal4ACT-Notch1IC (pLC8) was
generated from the Notch1 plasmid pJH142 (25). DBD-SKIP was
expressed in pJH313, Gal4DBD-C. elegans SKIP was expressed in pLC2, Gal4DBD-D. melanogaster SKIP was expressed in pLC3,
Lag1-Gal4ACT was expressed in pLC1, and DBD-EBNA2(252-425) was
expressed in pJH357. Bacterially expressed glutathione
S-transferase (GST) fusions were generated in the pGEX2T
(Promega)-derived plasmid pGH413; GST-CBF1(1-500) was expressed in pJH163.
(ii) Eukaryotic expression plasmids.
Gal4DBD fusions were
expressed from a simian virus 40 promoter in the pGH250 vector
background. Gal4-CBF1(1-500) was expressed in pJH93, Gal4-SKIP(1-536)
was expressed in pJH274, Gal4-C. elegans SKIP was expressed
in pJH470, and Gal4-D. melanogaster SKIP was expressed in
pJH364. The SG5 vector (Stratagene) was modified to incorporate either
Flag (pJH253), hemagglutinin (HA) (pHYC66), or Myc (pJH363) epitopes.
These vectors were used to generate Flag-SKIP (pJH281), Myc-CBF1
(pMF1), and HA-SKIP (pJH277). SG5-SKIP-Rta (pJH511) expresses SKIP
fused to the ACT (amino acids [aa] 520 to 605) of Epstein-Barr virus
(EBV) Rta (19). The rat Notch1IC (rNotch1IC) ankyrin repeat
mutant pBOS-FCDN1ank contains Notch1 aa 1747 to 2531 with an AA-to-EF
mutation in the fourth ankyrin repeat and is in pEF-BOS. The wild-type
rNotch1IC (aa 1747 to 2531) control plasmid was pBOS-FCDN1. Gal4-SMRT
(CMX-Gal-FSMRT) (8), Flag-SMRT (pCMX-PL2-SMRT Flag), and
SMRT expressed as a fusion with the herpes simplex virus VP16 ACT
(VP-SMRT) (pCMX-VP-FSMRT) (28) were obtained from R. Evans.
Expression vectors for Flag-Notch1IC(1751-2294) (pJH279),
HA-Notch1IC-E2TANLS (pJH208), Notch1ICRAM(1751-1864)-E2TANLS (pJH198),
and Notch2IC
RAM-E2TANLS(1822-2241) (pJH374) have been described
(23, 24, 38). The E2TANLS constructions are fused to the
EBNA2 transcriptional activation domain and nuclear localization signal
(aa 425 to 487) (40). The reporter plasmids 5× Gal4TK-CAT, thymidine kinase (TK)-luciferase, 8× wtCBF1-luciferase, 8×
mtCBF1-luciferase, and 4× Cp-CAT have been previously described
(23, 39, 40).
Yeast two-hybrid assays.
The yeast two-hybrid screen and
yeast assays for SKIP interactions were performed with yeast strain
Y190 as previously described (25). Beta-galactosidase
activity was measured from three independent cotransformants using
2-nitrophenyl
-D-galactopyranoside as the substrate. The
amount of 2-nitrophenol liberated after 2 to 4 h of incubation was
measured by determining absorbance at 420 nm.
CAT and luciferase assays.
HeLa cells were maintained in
Dulbecco modified Eagle medium (DMEM) plus 10% fetal calf serum and
plated at 1.2 × 105 cells per well in six-well plates
(Nunc) 1 day prior to transfection. Cells were transfected using the
calcium phosphate procedure, and cultures received 0.8 µg of 5×
Gal4TK-CAT, 4× Cp-CAT, 8× wtCBF1-luciferase or 8× mtCBF1-luciferase
reporter, 0.5 µg of the Gal4 vector or Gal4 fusion plasmid, 0.5 µg
of EBNA2 or the NotchIC effector plasmid, and 1 µg of TK-luciferase
as an internal control for transfection efficiency. The total DNA was
kept constant for each sample using the vector plasmid. Each experiment
was repeated at least two times. Chloramphenicol acetyltransferase
(CAT) and luciferase assays were performed as previously described
(23).
Immunoprecipitation and Western blotting.
293T cells seeded
at 106 per 10-cm-diameter culture dish were transfected
with 8 µg of expression plasmid using the calcium phosphate method.
Two days after transfection, the cells were washed and lysed in 2.5 ml
of ice-cold lysis buffer (0.1% sodium dodecyl sulfate, 1% deoxycholic
acid, 0.5% NP-40, 0.2 mM phenylmethylsulfonyl fluoride, and 2 µg of
aprotinin in phosphate-buffered saline per ml). The cell suspension was
passed five times through a 20-gauge syringe needle, and the extract
was clarified by centrifugation for 10 min at 15,000 rpm in a Sorvall
MC12V microcentrifuge. Anti-Flag or anti-Myc mouse monoclonal
antibodies (Sigma) and anti-CBF1, anti-Notch, or anti-SKIP rabbit
polyclonal antibodies were mixed with protein A-Sepharose 4B (20 µl;
Pharmacia) in 60 µl of lysis buffer and incubated at 4°C for 2 h. The beads were blocked with 3% skim milk in lysis buffer for 15 min
and washed three times in lysis buffer. One milliliter of cell extract
was added to the beads and incubated for 2 h at 4°C. The beads
were then washed six times with lysis buffer and mixed with 35 µl of
sample buffer. Samples (5 to 25 µl) were subjected to electrophoresis
using a 9% denaturing polyacrylamide gel. The amount of sample used
for direct immunoprecipitations was one-quarter of the amount used for
the coimmunoprecipitated sample. Western blot analysis was performed
using peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G
secondary antibodies and the enhanced-chemiluminescence system
(Amersham). Rabbit anti-CBF1 polyclonal antisera were generated using
the peptide Y-P-G-K-F-G-E-R-P-P-P-K-R-L-T-R-S-C as the immunogen, and
rabbit anti-Notch1 antisera were generated using the peptide Y-G-D-E-D-L-E-T-K-K-F-R-F-E-E-P-S-C as the immunogen. Molecular mass
standards were purchased from Gibco BRL.
GST-protein affinity assays.
293T cells were transfected in
10-cm-diameter dishes with 12 µg of each plasmid. Extracts were
prepared 2 days after transfection by washing the cells with
phosphate-buffered saline, followed by lysis in ice-cold lysis buffer
(0.2% NP-40, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 5% glycerol, 0.2 mM
phenylmethylsulfonyl fluoride, 2 µg of aprotinin in Tris-HCl [pH
7.4] per ml). The suspension was sonicated for 15 s on ice and
clarified by centrifugation for 10 min at 15,000 rpm.
Extracts from bacterial cells induced to express GST-CBF1 were prepared
by standard procedures. These extracts were incubated for 2 h at
4°C with 20 µl of glutathione-Sepharose 4B beads (Pharmacia). After
three washes in lysis buffer, the bound GST fusion proteins were
incubated for 2 h at 4°C with transfected 293T cell extract. The
beads were then washed six times in lysis buffer and added to 30 µl
of sample buffer. Samples were electrophoresed through sodium dodecyl
sulfate-9% polyacrylamide gels, the separated proteins were
transferred to a nitrocellulose membrane, and proteins were detected by
Western blotting as described above.
Muscle cell differentiation assays.
The C2C12 cell line is a
clonal mouse cell population that proliferates as mononuclear myoblasts
in growth medium (DMEM plus 10% fetal bovine serum and 5% cosmic calf
serum). These cells undergo morphological and molecular changes that
correlate with muscle cell differentiation when they are switched to
differentiation medium (DMEM plus 10% horse serum). CDN2 cells are
C2C12 cells selected for expression of the Notch2 intracellular domain.
Muscle cell differentiation is blocked by NotchIC in these cells. The open reading frame of SKIP was cloned in the pREP4 vector in either the
sense (pSZ20) or antisense (pSZ21) direction, and the plasmids were
transfected into CDN2 cells. Stably transfected cell lines were
generated using hygromycin selection (250 µg/ml). The muscle fusion
assays were performed essentially as previously described (24). Briefly, C2C12, CDN2, CDN2-SKIP (CDN2 cells
overexpressing SKIP), and CDN2-asSKIP (CDN2 cells expressing antisense
SKIP) were plated in 100-mm-diameter dishes in growth medium. When the cells were 80% confluent, they were switched to differentiation medium
and monitored daily. The differentiation medium was changed every two
days. After 6 days of differentiation induction, the cells were photographed.
 |
RESULTS |
SKIP and SKIP homologs interact with CBF1.
We identified SKIP
as a CBF1-interacting protein in a yeast two-hybrid screen. Members of
both the CBF1 and the Notch family of proteins are highly conserved
across species. Database comparisons also indicate that SKIP has
homologs in C. elegans and D. melanogaster that
exhibit a high level of amino acid conservation (Fig.
1). We first sought to verify the
SKIP-CBF1 interaction. A GST-affinity assay was performed (Fig.
2A) using extract from 293T cells
transfected with Flag-SKIP. Binding of Flag-SKIP was detected by
Western blot analysis of the bound proteins and probing with anti-Flag
monoclonal antibody. Flag-SKIP did not bind to GST (Fig. 2A, lane 1)
but did bind to GST-CBF1 (Fig. 2A, lane 2). The presence of Flag-SKIP in the transfected extract is shown in Fig. 2A, lane 3, and the identity of Flag-SKIP was further confirmed by direct
immunoprecipitation of Flag-SKIP from the transfected cell extract
using anti-Flag monoclonal antibody (Fig. 2A, lane 4).

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of the human SKIP protein sequence with the
C. elegans (CeSKIP) (accession no. Z74045) and D. melanogaster (DmSKIP) (accession no. [Dbx42] X64536) homologs
illustrating the high degree of amino acid conservation. Shading within
the outlined areas indicates amino acid identity, and no shading in the
outlined areas indicates conservative changes. The alignment was
generated using MacVector (Oxford Molecular Group).
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 2.
SKIP and its homologs interact with CBF1. (A)
GST-affinity assay showing binding of Flag-SKIP to GST-CBF1 (lane 2)
but not to GST (lane 1). Positive control lanes contained transfected
cell extract (10 µl) (lane 3) and Flag-SKIP that was
immunoprecipitated (IP) with mouse anti-Flag monoclonal antibody (lane
4). The vertical bar indicates the position of the immunoglobulin heavy
chain. (B) SKIP-CBF1 interactions are evolutionarily conserved. Yeast
two-hybrid assay in which interaction is measured by induction of
beta-galactosidase activity. SNF1-SNF4 (lane 1) and EBNA2-CBF1 (lane 2)
formed positive controls, while the SKIP-ACT vector pairing (lane 9)
formed the negative control. SKIP, C. elegans SKIP (CeSKIP),
and D. melanogaster SKIP (DmSKIP) (lanes 3 to 5) each showed
interaction with CBF1. Furthermore the SKIP, C. elegans
SKIP, and Drosophila SKIP interactions could also be
demonstrated using the C. elegans CBF1 homolog Lag-1 as the
interacting partner (lanes 7 to 9). The results shown are averages of
results of three experiments, with the standard deviations indicated.
|
|
To address the biological relevance of the CBF1-SKIP interaction, we
performed a yeast two-hybrid assay to determine whether
the SKIP-CBF1
interaction was conserved across species. Interaction
between Gal4-DBD
fusion proteins and Gal4-ACT fusion proteins
in cotransformed yeast was
measured by induction of beta-galactosidase
activity. Two pairs of
proteins known to be interacting partners,
SNF1 plus SNF4 and CBF1 plus
EBV EBNA2, were included in the assay
(Fig.
2B, lanes 1 and 2). SKIP
plus the Gal4-ACT vector formed
the negative control (Fig.
2B, lane 9).
In this assay, both
C. elegans SKIP and
Drosophila SKIP interacted with CBF1 as effectively
as SKIP
(Fig.
2B, lanes 3 to 5). The degree of conservation of
the CBF1 and
SKIP interaction domains across species was further
emphasized by the
demonstration that the
C. elegans CBF1 homolog
Lag-1 not
only interacted with
C. elegans SKIP but also retained
interaction with SKIP and
Drosophila SKIP (Fig.
2B, lanes 6 to
8).
SKIP mediates transcriptional repression.
To ascertain the
role of SKIP in the CBF1-associated complex, we generated Gal4-SKIP
fusion proteins and examined the properties of these fusion proteins in
transient-expression assays. Cotransfection of the Gal4-SKIP expression
plasmids into HeLa cells with a CAT reporter containing five upstream
Gal4 binding sites, 5× Gal4TK-CAT, led to repression of reporter CAT
expression (Fig. 3). The repression mediated by Gal4-SKIP was comparable to that induced by Gal4-CBF1. The
Drosophila SKIP fusion also mediated transcriptional
repression, indicating conservation of function as well as conservation
of interaction with CBF1. Gal4-C. elegans SKIP induced a
mild repression of reporter CAT expression. The C. elegans
SKIP protein may be less effective than SKIP and Drosophila
SKIP at mediating contacts with other mammalian proteins required for
transcriptional repression.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
SKIP mediates transcriptional repression. Shown are
results of a transient-expression assay demonstrating repression of the
5× Gal4TK-CAT reporter by Gal4-SKIP fusion proteins. SKIP, C. elegans SKIP (CeSKIP), and Drosophila SKIP (DmSKIP)
expressed as fusions with Gal4(1-147) were cotransfected into HeLa
cells with the 5× Gal4TK-CAT reporter (0.8 µg) and 1 µg of
TK-luciferase as a control for transfection efficiency.
|
|
The ability of Gal4-SKIP to function as a transcriptional repressor
suggested that SKIP might interact with proteins in the
CBF1
corepressor complex. SMRT is a key component of the CBF1
corepressor
complex (
28). Interaction between SKIP and SMRT
was tested
in a mammalian two-hybrid assay in HeLa cells cotransfected
with a 5×
Gal4TK-CAT reporter, Gal4-SKIP, and VP-SMRT (
28) (Fig.
4A). Gal4-SKIP repressed expression
of the CAT reporter. However,
reporter expression was activated by the
addition of VP-SMRT.
This activation is indicative of an interaction
between SMRT and
the promoter-bound Gal4-SKIP which results in bringing
the VP16
activation domain of VP-SMRT to the promoter. The same
activation
was also observed when SMRT was expressed as the DNA binding
partner
(Gal4-SMRT), and SKIP was expressed as a fusion with the
transcriptional
ACT from the EBV Rta transactivator (SKIP-Rta) (Fig.
4A). Gal4-SMRT
weakly repressed expression from 5× Gal4TK-CAT.
Cotransfection
of SKIP-Rta resulted in strong reporter activation,
which is consistent
with an interaction between SKIP and the
promoter-bound Gal4-SMRT
that brings the Rta ACT to the promoter. Thus,
SKIP appears to
mediate repression through either direct or indirect
contacts
with SMRT and the CBF1 corepressor complex.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
SKIP interacts with SMRT in addition to CBF1. (A)
Mammalian two-hybrid assay demonstrating interaction between SKIP and
the corepressor SMRT. Cotransfection into HeLa cells of Gal4-SKIP or
Gal4-SMRT repressed expression from the 5× Gal4TK-CAT reporter.
Addition of SMRT fused to the ACT of herpes simplex virus VP16
(VP-SMRT) activated CAT expression, indicating interaction between SMRT
and the reporter-bound Gal4-SKIP. This interaction was confirmed using
the complementary pairing in which addition of SKIP fused to the ACT of
the EBV Rta transactivator (SKIP-Rta) activated expression through
reporter-bound Gal4-SMRT. TK-luciferase was cotransfected as a control
for transfection efficiency. (B) Yeast two-hybrid assay demonstrating
that the SKIP interaction site on CBF1 is separable from the SMRT
interaction site. Induction of beta-galactosidase activity was used as
a measure of interaction. As described by others (28), SMRT
interacts with CBF1 (lane 1) but not with CBF1(EEF233AAA) (mt233). SKIP
interacts with CBF1 (lane 3) and with mt233 (lane 4). The SKIP-DBD
vector pairing formed the negative control (lane 5). The SKIP-SMRT
interaction can also be demonstrated in the yeast assay (lane 6). The
results shown are averages of results of three experiments, with the
standard deviations indicated.
|
|
To address whether SKIP contacted the SMRT corepressor complex
independently of SKIP contacts with CBF1, a yeast two-hybrid
assay was
performed to examine the effect of the CBF1(EEF233AAA)
mutation (Fig.
4B). Beta-galactosidase activity was induced in
the yeast assay when
Gal4DBD-CBF1 was paired with Gal4ACT-SMRT,
and in confirmation of
previous results (
28), the interaction
with SMRT was
abolished by a mutation at codon 233 of CBF1 (mt233)
(Fig.
4B, lanes 1 and 2). In contrast to the result obtained with
SMRT, the Gal4DBD-mt233
was just as effective as wild-type CBF1
in interacting with SKIP (Fig.
4B, lanes 3 and 4). This observation
indicates that the SKIP
interaction interface on CBF1 is distinguishable
from the SMRT
interaction site and that SKIP interacts with CBF1
independently of its
interaction with SMRT. The SKIP-SMRT interaction
shown by the mammalian
two-hybrid assay in Fig.
4A could also
be demonstrated in yeast (Fig.
4B, lane
6).
NotchIC interacts with SKIP.
NotchIC is known to interact with
CBF1 (22, 23, 26, 28). To better understand how NotchIC
overcomes CBF1-mediated transcriptional repression, we evaluated
whether there were also interactions between NotchIC and SKIP. An
immunoprecipitation assay was performed using extracts of 293T cells
cotransfected with Flag-SKIP and HA-NotchIC (Fig.
5A). Immunoprecipitated proteins were
analyzed by Western blotting, and Flag-SKIP was detected using
anti-Flag monoclonal antibody. Flag-SKIP coprecipitated with HA-NotchIC
in immunoprecipitates generated using anti-Notch rabbit antiserum (Fig.
5A, lane 3). The coprecipitated Flag-SKIP had the same mobility in the
gel as Flag-SKIP directly precipitated with anti-SKIP rabbit antibody
(Fig. 5A, lane 1) or directly precipitated with anti-Flag monoclonal
antibody (Fig. 5A, lanes 2 and 6).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
NotchIC interacts with SKIP. (A) Immunoprecipitation
assay using extracts of cells cotransfected with Flag-SKIP and NotchIC.
A Western blot of the immunoprecipitates was probed with anti-Flag
antibody to detect Flag-SKIP. Flag-SKIP was directly precipitated by
rabbit anti-SKIP antibody (lane 1) and by anti-Flag monoclonal antibody
(lanes 2 and 6). Flag-SKIP also coprecipitated with NotchIC in
immunoprecipitates formed by anti-Notch rabbit antibody (lane 3).
Transfected cell extract (10 µl) was loaded in lane 4. Flag-SKIP was
not coprecipitated by rabbit preimmune serum (lane 5) or by an
irrelevant mouse monoclonal antibody (anti-CD23; lane 7). The amount of
extract used for direct precipitations was one-quarter of that used for
coprecipitations. The vertical bar indicates the position of the
immunoglobulin heavy chain. Ab, antibody; cont., control. (B) The
Notch-SKIP interaction is conserved across species. Shown are the
results of a yeast two-hybrid assay in which protein-protein
interaction is measured by induction of beta-galactosidase activity.
The SKIP-plus-ACT vector interaction (lane 4) formed the negative
control. NotchIC interacted equally with SKIP, C. elegans
SKIP (CeSKIP), and Drosophila SKIP (DmSKIP) (lanes 1 to 3).
The results shown are averages from three experiments, with the
standard deviations indicated.
|
|
Again, we obtained evidence for a high degree of conservation of the
NotchIC-SKIP interaction across species. A yeast two-hybrid
assay in
which yeast cells were cotransformed with Gal4ACT-NotchIC
and Gal4DBD
fusions with SKIP,
C. elegans SKIP, or
Drosophila SKIP revealed comparable levels of induction of beta-galactosidase
enzyme activity with all three SKIP homologs (Fig.
5B, lanes 1
to 3).
Cotransformation of yeast with Gal4DBD-SKIP and the Gal4ACT
vector
formed the negative control in this assay (Fig.
5B, lane
4). In
summary, the protein-protein interaction assays indicated
that NotchIC
interacts with SKIP in addition to CBF1, as previously
recognized.
The NotchIC-SKIP interaction is separable from the NotchIC-CBF1
interaction.
SKIP acted as a repressor when it was expressed as a
Gal4 fusion protein (Fig. 3) and, consistent with that observation,
interacted with the SMRT corepressor (Fig. 4A). Therefore, the finding
that SKIP interacted with NotchIC was somewhat unexpected. Since
NotchIC interacts with CBF1 and SKIP also interacts with CBF1, the
possibility existed that the NotchIC-SKIP interaction that we detected
was really indirect and was CBF1 mediated, i.e., that NotchIC
interacted with CBF1 and CBF1 in turn interacted with SKIP but that
NotchIC and SKIP did not make direct contacts. To determine whether
CBF1 was a necessary intermediate for NotchIC-SKIP interaction, we performed a mammalian two-hybrid assay with NotchIC expressed as a
fusion with the transactivation domain and nuclear localization signal
of EBV EBNA2 (NIC-E2TA) and two NotchIC variants: one in which the CBF1
interaction domain (RAM domain) of NotchIC was expressed as a fusion
with the E2TA domain [NIC(RAM)-E2TA] and the other in which a
NotchIC-E2TA fusion was deleted for the RAM domain (NIC
RAM-E2TA)
(Fig. 6). Expression from the 5×
Gal4TK-CAT reporter was repressed by cotransfection of Gal4-SKIP.
Expression was increased by cotransfection of NIC-E2TA, indicative of
an interaction between NotchIC and the reporter-bound Gal4-SKIP. No
increase in expression was seen on cotransfection of NIC(RAM)-E2TA, implying that the RAM domain was unable to mediate contacts with Gal4-SKIP. [The NIC(RAM)-E2TA construction has previously been shown
to be able to activate expression of 5× Gal4TK-CAT in the presence of
Gal4-CBF1 and therefore is capable of binding to CBF1 (23)]. Deletion of the RAM domain from NotchIC did not
impair the ability of the NIC
RAM-E2TA construction to activate
expression from 5× Gal4TK-CAT. Thus, the RAM domain is neither
sufficient nor necessary for NotchIC interaction with SKIP and the
domain on NotchIC that contacts SKIP is separable from the CBF1
interaction domain.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
NotchIC interaction with SKIP is independent of the
NotchIC-CBF1 interaction. The results of a mammalian two-hybrid assay
show that the CBF1-interacting domain, NotchIC(RAM), is neither
required nor sufficient to mediate interaction with SKIP. HeLa cells
were transfected with the 5× Gal4TK-CAT reporter, Gal4-SKIP, and the
indicated NotchIC-EBNA2 transactivation domain (E2TA) fusion
constructions. TK-luciferase was included as a control for transfection
efficiency. The NIC(RAM)-E2TA fusion protein expresses only the CBF1
interaction domain (RAM domain) of NotchIC and is unable to mediate
activation of the 5× Gal4TK-CAT reporter. The NIC RAM-E2TA fusion
expresses a NotchIC that has the RAM domain deleted and is capable of
mediating reporter activation.
|
|
SMRT displaces NotchIC from both CBF1 and SKIP.
SMRT has been
shown to compete with NotchIC for binding to CBF1 (28). To
better understand the consequences of the SKIP interaction with CBF1,
we compared the effects of the addition of SKIP with the effects of the
addition of SMRT in a mammalian two-hybrid assay of NotchIC
transactivation. HeLa cells were cotransfected with the 5× Gal4TK-CAT
reporter, Gal4-CBF1, NotchIC, and increasing amounts of SKIP or SMRT
expression vectors (Fig. 7A). As
expected, cotransfection of Gal4-CBF1 repressed CAT expression from the 5× Gal4TK-CAT reporter and the addition of NotchIC led to reporter activation through NotchIC interaction with reporter-bound Gal4-CBF1. The addition of SMRT abolished NotchIC activation. This is consistent with the results of a previous report (28) of competition
between SMRT and NotchIC for binding to CBF1. In contrast, the addition of SKIP had a small positive effect on NotchIC activation of the 5×
Gal4TK-CAT reporter, suggesting that SKIP does not function like SMRT
to compete for NotchIC binding to CBF1 but may instead facilitate the
NotchIC-CBF1 interaction. This interpretation was strengthened by the
observation that cotransfection of SKIP could partially restore the
ability of RAM-deleted NotchIC to activate a luciferase reporter
containing eight copies of the wild-type CBF1 binding site (8× wtCBF1
BS-Luc) (data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
SMRT competes with NotchIC for contacts on both CBF1 and
SKIP. (A) Competition two-hybrid assay of HeLa cells transfected with
the 5x Gal4TK-CAT reporter, Gal4-CBF1, NotchIC, and increasing amounts
(0.1, 0.5, and 2 µg) of SKIP or SMRT. TK-luciferase was included as
an internal control. Introduction of SKIP had a mild positive effect on
NotchIC activation of the Gal4-CBF1-bound reporter, whereas SMRT
abolished NotchIC activation. (B) Competition two-hybrid assay of HeLa
cells transfected with the 5× Gal4TK-CAT reporter, Gal4-SKIP,
NotchIC( RAM)-E2TA, and increasing amounts (0.1, 0.5, and 2 µg) of
SMRT. TK-luciferase was included as an internal control. Activation of
the Gal4-SKIP-bound reporter by the non-CBF1-interacting
NotchIC( RAM)-E2TA fusion protein was also abolished by SMRT.
|
|
The protein-protein interaction data indicated that SKIP contacted both
the SMRT corepressor complex and the NotchIC activator.
We next
addressed whether there was competition between SMRT and
NotchIC for
binding to SKIP. A second mammalian two-hybrid assay
was performed in
which the effect of the addition of SMRT on NotchIC
interaction with
Gal4-SKIP was examined (Fig.
7B). HeLa cells
were cotransfected with
the 5× Gal4TK-CAT reporter, Gal4-SKIP,
NotchIC, and increasing amounts
of SMRT. The NotchIC(

RAM-E2TA)
version of NotchIC was used in
this assay to eliminate any CBF1
interactions that might occur through
the RAM domain and complicate
analysis of the results. In this assay,
Gal4-SKIP repressed expression
from the 5× Gal4TK-CAT reporter and the
addition of NotchIC(

RAM-E2TA)
activated expression through tethering
of NotchIC(

RAM-E2TA) to
reporter-bound Gal4-SKIP.
Cotransfection of SMRT diminished the
ability of
NotchIC(

RAM-E2TA) to activate the 5× Gal4TK-CAT reporter.
The
SMRT-induced effect occurred in a dose-responsive manner.
The
competition data are consistent with a model in which binding
of SMRT
and NotchIC to SKIP are mutually exclusive
events.
NotchIC mutated in the fourth ankyrin repeat is unable to interact
with SKIP.
A Notch mutant that has been used in a number of
studies carries a 2-aa change in the fourth ankyrin repeat. This M2
mutant is unable to block muscle cell differentiation (30)
and unable to activate the HES-1 promoter (26). A version of
rat NotchIC carrying this mutation was generated along with a wild-type
rat NotchIC control. The NotchIC(ank) mutant was functionally impaired, as illustrated in a transient-expression assay in which the wild-type or mutant NotchIC expression vectors were cotransfected with 8× wtCBF1
BS-Luc (Fig. 8A). The reporter was
activated approximately 85-fold by the parental NotchIC construction
but only 7-fold by the ankyrin mutant NotchIC. To demonstrate the
specificity of the activation, the assay was repeated using a
luciferase reporter containing eight copies of a mutated CBF1 binding
site (8× mtCBF1 BS-Luc) (Fig. 8B). Neither wild-type nor mutant
NotchIC activated expression from this reporter.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 8.
NotchIC mutated in the fourth ankyrin repeat has
impaired ability to activate a reporter containing CBF1 binding sites.
(A) Transient-expression assay of HeLa cells cotransfected with 8×
wtCBF1 BS-Luc and either wild-type NotchIC (wtN1IC) or an ankyrin
repeat NotchIC mutant [N1IC(ank)] as indicated. (B)
Transient-expression assay performed as described for panel A but with
8× mtCBF1 BS-Luc. The reporter carrying mutated CBF1 binding sites was
not responsive to wild-type or mutant NotchIC.
|
|
We next examined the ability of the NotchIC ankyrin repeat mutant to
bind to CBF1 and SKIP. Coimmunoprecipitation assays were
performed on
extracts of 293T cells cotransfected with Flag-CBF1
plus wild-type or
mutant NotchIC or cotransfected with Flag-SKIP
plus wild-type or mutant
NotchIC. The precipitated proteins were
analyzed on Western blots which
were probed with anti-Flag monoclonal
antibody to detect Flag-CBF1 and
Flag-SKIP. As illustrated in
Fig.
9A,
Flag-CBF1 coprecipitated with both wild-type and mutant
NotchIC (lanes
1 and 4). Flag-CBF1 directly precipitated from
the extract with
anti-Flag antibody is shown in lanes 2 and 5.
The ability of mutant
NotchIC to coprecipitate with Flag-CBF1
indicates that the ankyrin
repeat mutation does not interfere
with interactions between NotchIC
and CBF1.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 9.
Mutation of the fourth ankyrin repeat does not affect
NotchIC interaction with CBF1 but abolishes NotchIC SKIP interaction.
(A) Coimmunoprecipitation assay using extracts of cells cotransfected
with the wild-type (wt) or ankyrin repeat mutant NotchIC [mt
NotchIC(ank)] and either Flag-CBF1 or Flag-SKIP. Western blots of the
immunoprecipitated proteins were probed with mouse anti-Flag monoclonal
antibody to detect Flag-CBF1 (lanes 1 to 6) or Flag-SKIP (lanes 7 to
12). Flag-CBF1 coprecipitated with both wild-type and mutant NotchIC
(lanes 1 and 4), whereas Flag-SKIP coprecipitated with wild-type but
not mutant NotchIC (lanes 7 and 10, respectively). Lane 1, coprecipitation with anti-Notch rabbit antibody; lane 2, direct
precipitation with anti-CBF1 rabbit antibody; lane 3, transfected cell
extract (10 µl); lane 4, coprecipitation with anti-Notch rabbit
antibody; lane 5, direct precipitation with anti-CBF1 rabbit antibody;
lane 6, transfected cell extract (10 µl); lane 7, coprecipitation
with anti-Notch rabbit antibody; lane 8, direct precipitation with
anti-SKIP rabbit antibody; lane 9, transfected cell extract (10 µl);
lane 10, coprecipitation with anti-Notch rabbit antibody; lane 11, direct precipitation with anti-SKIP rabbit antibody; lane 12, transfected cell extract (10 µl). The amount of extract used for
direct precipitations was one-quarter of that used for
coprecipitations. The vertical bar indicates the position of the
immunoglobulin heavy chain. IP, immunoprecipitation; Ab, antibody. (B)
Schematic of the Notch protein showing the relative locations of the
CBF1 and SKIP binding domains and the location of the ankyrin repeat
mutation. TM, transmembrane domain. EGF, epidermal growth factor; PEST,
protein turnover motif.
|
|
Figure
9A (lanes 7 to 12) presents the analysis of SKIP interaction
with the wild-type and mutant NotchIC proteins. Immunoprecipitation
of
wild-type NotchIC with anti-Notch rabbit antiserum resulted
in
coprecipitation of Flag-SKIP (lane 7). However, Flag-SKIP did
not
coprecipitate with the mutant NotchIC (lane 10). The anti-Notch
rabbit
antiserum used to precipitate NotchIC was raised against
an
epitope at the carboxy terminus of NotchIC, and this
antiserum
recognizes mutant NotchIC as effectively as wild-type
NotchIC.
The coprecipitation of Flag-CBF1 with mutant NotchIC in
immunoprecipitates
generated with the anti-NotchIC rabbit antiserum
indicated that
proteins that interact with mutant NotchIC are
detectable by coimmunoprecipitation
with this antiserum (Fig.
9A, lane
4). Direct immunoprecipitation
from the transfected cell extracts of
Flag-SKIP by anti-Flag monoclonal
antibody is shown in lanes 8 and 11. To summarize, the NotchIC
ankyrin repeat mutant retained the ability to
interact with CBF1
but lost the ability to interact with SKIP. The
relative locations
of the CBF1 and SKIP interaction domains on Notch
are illustrated
in Fig.
9B.
The ability of NotchIC to block muscle cell differentiation is
impaired in cells expressing antisense SKIP.
We have shown that
mutation of the fourth ankyrin repeat of NotchIC abolished NotchIC
interaction with SKIP and interfered with NotchIC transactivation
function in a transient-expression assay. To strengthen the concept
that SKIP is an important contributor to NotchIC activity, we examined
the effect of constituitive expression of sense and antisense SKIP on
NotchIC function in a muscle differentiation assay.
C2C12 myoblasts proliferate in an undifferentiated state when they are
grown in medium containing fetal bovine serum, but
the cells undergo
growth arrest and differentiate to form myotubes
when they are switched
to medium containing horse serum (Fig.
10a and
b). Constituitive expression of NotchIC
in C2C12 cells
blocks myoblast differentiation. This is illustrated in
Fig.
10c
and d by using the previously described C2C12-derived cell
line
CDN2 (
24). In medium containing fetal bovine serum,
CDN2 cells
grow as undifferentiated myoblasts that are morphologically
indistinguishable
from the parental C2C12 cells (Fig.
10c). However,
culturing in
medium containing horse serum does not lead to growth
arrest or
myoblast formation. The CDN2 cells continue to proliferate in
an undifferentiated state (Fig.
10d).

View larger version (130K):
[in this window]
[in a new window]
|
FIG. 10.
Muscle differentiation assay showing blockage of
NotchIC function by antisense SKIP. Photomicrographs of C2C12 and
C2C12-derived cell lines in growth medium (a, c, e, and g) or after 6 days in differentiation medium (b, d, f, and h). In differentiation
medium, C2C12 cells fused to form myotubes (b) whereas the CDN2 cells,
which constitutively express Notch2IC, continued to grow as
undifferentiated myoblasts (d). In antisense-SKIP-expressing
CDN2-asSKIP cells, myotubes formed that had the same morphology as
those formed by C2C12 cells (f). This differentiation was not observed
in sense-SKIP-expressing CDN2-SKIP cells (h).
|
|
We introduced a vector expressing either sense or antisense SKIP into
CDN2 cells. The vector also contained a gene for hygromycin
resistance,
and drug-resistant cell lines were selected. The expression
of sense
and antisense SKIP transcripts in the CDN2-SKIP and CDN2-asSKIP
cell
lines was confirmed by reverse transcription-PCR (data not
shown).
Constituitive expression of SKIP in the CDN2 cells did
not have a
significant effect on their growth phenotype. In medium
containing
bovine serum, the cells grew as undifferentiated myoblasts
(Fig.
10g),
and on conversion to differentiation medium, the cells
continued to
proliferate in an undifferentiated state in a manner
similar to that of
the parental CDN2 cells (Fig.
10h). In contrast,
expression of
antisense SKIP had a marked effect. In medium containing
bovine serum,
the CDN2-asSKIP cells grew as undifferentiated myoblasts
(Fig.
10e).
However, when they were placed in differentiation medium,
the
CDN2-asSKIP cells, unlike the parental CDN2 cells, were able
to
differentiate and form myotubes (Fig.
10f).
The combined protein-protein interaction and functional data indicate
that interaction with CBF1 alone is not adequate for
full NotchIC
function and further suggest that binding to SKIP
is required for
NotchIC to efficiently activate CBF1-bound promoters.
The model for
NotchIC activation of CBF1-repressed promoters that
derives from this
study is presented in Fig.
11.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 11.
Model for Notch activation of CBF1-repressed promoters.
CBF1 binds promoters carrying the sequence GTGGGAA. SKIP
interacts with CBF1. SMRT contacts both SKIP and CBF1. SMRT is linked
to a corepressor complex that includes Sin3A, SAP30, CIR, HDAC1, and
HDAC2 (25, 28) and mediates promoter repression through
chromatin remodeling. NotchIC competes with SMRT for contacts on both
CBF1 and SKIP. Displacement of the corepressor complex relieves
repression, and the promoter is further activated through the
endogenous NotchIC transcriptional ACT. Loss of CBF1 interaction
through mutation of the RAM domain or loss of interaction with SKIP
through mutation of the fourth ankyrin repeat cripples the ability of
NotchIC to activate CBF1-repressed promoters.
|
|
 |
DISCUSSION |
Evidence has accumulated that ligand-induced Notch signaling is
associated with proteolytic cleavage events that result in the release
of NotchIC and its translocation into the nucleus. The pathways by
which intranuclear NotchIC modulates transcription are not fully
understood, but a major intranuclear target for NotchIC is the CSL
family of DNA binding proteins. The human CSL protein CBF1 acts as a
transcriptional repressor through tethering of a corepressor complex
that has been shown to include the proteins SMRT, CIR, SAP30, HDAC1,
and HDAC2 (25, 28). The model of transcriptional repression
that has emerged from studies of the nuclear hormone receptors and the
Mad-Myc-Max family of proteins is one in which a DNA binding protein
tethers the corepressor N-CoRs or the related SMRT, which in turn are
participants in a complex that also contains Sin3A or -B, a variety of
Sin3-associated proteins, including SAP30, SAP18, RbAp46, and RbAp48,
and HDAC1 and HDAC2 (1, 20, 21, 33, 34, 42, 61, 62). The involvement of the corepressor complex in CBF1-mediated repression was
originally substantiated through the use of a CBF1 repression-minus mutant, CBF1(EEF233), which was shown to have lost interaction with
both the SMRT and CIR proteins of the corepressor complex (25,
28).
Our yeast two-hybrid screen identified SKIP as a CBF1-interacting
protein, and we presented evidence for interaction between SKIP and the
SMRT corepressor. SKIP was originally identified as a Ski-interacting
protein and as a component of the vitamin D receptor (5,
10). Recently, c-Ski has been shown to be a component of the
thyroid hormone receptor and Mad corepressor complexes and to bind both
N-CoR and Sin3A (44). A trait shared by the nuclear hormone
receptors and CBF1 is that these proteins mediate not only
transcriptional repression but also transcriptional activation. In the
absence of ligand, thyroid hormone and retinoic acid receptors interact
with SMRT or N-CoR through the ligand binding domain to mediate
repression. Binding of hormone causes dissociation of the corepressor
complex and recruitment of a coactivator complex to produce
transcriptional activation. DNA-bound CBF1 is converted from a
transcriptional repressor into an activator in two known circumstances:
in response to Notch signaling and in the presence of the EBV EBNA2
protein. Both NotchIC and EBNA2 bind to the repression domain of CBF1
(22, 23). SMRT competes with NotchIC for binding to CBF1
(28), and we have found that there is similar competition
between SMRT and EBNA2 for binding to CBF1 (63).
The identification of SKIP as a CBF1-interacting protein provides
additional insight into the mechanism by which NotchIC converts CBF1
into a mediator of transcriptional activation. SKIP appears to serve as
a tether protein for both the SMRT corepressor and NotchIC. In contrast
to SMRT, SKIP does not compete NotchIC from CBF1 but rather seems to
facilitate NotchIC binding. Furthermore, the binding of SMRT and
NotchIC to SKIP is mutually exclusive. SMRT competed with NotchIC for
binding to SKIP. Thus, the conversion from transcriptional repression
to activation involves both CBF1- and SKIP-exchanging partners from the
SMRT-corepressor complex to a NotchIC activation complex.
The importance of SKIP contacts for NotchIC function was illustrated by
the inability of NotchIC to block muscle cell differention when
antisense SKIP was constituitively expressed in the cells and by the
behavior of NotchIC carrying a mutation in the fourth ankyrin repeat,
NotchIC(ank). The demonstration that NotchIC(ank) is unable to interact
with SKIP sheds light on at least one function of the NotchIC ankyrin
repeat domain. The integrity of the ankyrin repeat domain of NotchIC is
important for biological activity (37, 49, 50). Mutation of
two alanine residues in the fourth ankyrin repeat of Notch IC has
previously been found to ablate the ability of NotchIC to block muscle
cell differentiation and to impair the ability of NotchIC to activate
reporters carrying CBF1 binding sites (26, 30). The ankyrin
repeats have been assumed to directly contact CBF1. However, we found
that NotchIC carrying a double alanine mutation in the fourth ankrin
repeat retained the ability to bind CBF1 but had lost the ability to interact with SKIP. The C. elegans Notch homolog GLP-1 was
shown to interact directly with Lag-1 through the subtransmembrane RAM domain, while interaction between the ankyrin repeat domain of GLP-1
and Lag-1 appeared to be indirect, since it could be observed only in
colocalization assays with nematodes (50). This
interpretation of an indirect interaction between the ankyrin repeats
and Lag-1 is consistent with our demonstration that the ankyrin repeats directly interact with SKIP, which in turn interacts with CBF1.
NotchIC variants consisting solely of the ankyrin repeats are able to
elicit some of the responses of activated NotchIC. For example, a C2C12
cell line that constituitively expressed the NotchIC ankyrin repeat
domain did not form myotubes when cells were placed in differentiation
medium nor did these cells express differentiation markers such as
myogenin or myosin light chain (54). Similarly, nuclear
expression of the Drosophila Notch ankyrin repeats was
sufficient to block neuroblast segregations in Drosophila
embryos (55) and expression of the ankyrin repeat domain of
GLP-1 was able to regulate vulval cell fate in C. elegans (51). The ankyrin repeats also demonstrate transcriptional
activation activity (3, 50). We have previously shown that
transcriptional activation by NotchIC can be separated into two stages,
loss of repression (i.e., displacement of the corepressor complex) and activation mediated through the endogenous NotchIC activation domain
(23). In our model, SKIP acts as a tethering point for the
CBF1 corepressor complex to mediate repression and as a tethering point
for the ankyrin repeat domain of NotchIC during activation (Fig. 11).
Thus, overexpression of the ankyrin repeat domain may result in
displacement of the corepressor complex from CBF1 and relief of
promoter repression. In some instances, relief of repression alone may
be sufficient to alter transcriptional programming. However, NotchIC
also mediates CBF1-independent effects (43) and the ankyrin
repeats may also be involved in these activities.
The SKIP homologs in C. elegans and Drosophila
are highly conserved in amino acid sequence. In yeast interaction
assays we demonstrated that both the worm and fly SKIP homologs also
interact with CBF1/Lag-1 and with NotchIC. This conservation of
protein-protein interactions suggests that SKIP is likely to function
in Notch signaling analagously across species. The presence of SKIP in the vitamin D complex and c-Ski, a protein with which SKIP interacts, in the Mad and thyroid hormone receptor complexes also suggests that
SKIP may be a common tether for mammalian corepressor complexes. Furthermore, the role played by SKIP in orchestrating the
corepressor-to-activator switch on DNA-bound CBF1 may be conserved and
recapitulated in the nuclear hormone receptor and Mad complexes.
 |
ACKNOWLEDGMENTS |
We are grateful to R. Evans and J. Kimble for gifts of SMRT and
Lag-1 plasmids. We thank M. Chiu and M. Poderycki for technical assistance and F. Chang for help with manuscript preparation.
This work was supported by National Institutes of Health grants RO1
CA42245 to S.D.H. and RO1 NS31885 to G.W. G.W. also received support from STOP cancer.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Phone: (410) 955-2548. Fax:
(410) 955-8685. E-mail: dhayward{at}jhmi.edu.
 |
REFERENCES |
| 1.
|
Alland, L.,
R. Muhle,
H. Hou, Jr.,
J. Potes,
L. Chin,
N. Schreiber-Agus, and R. A. DePinho.
1997.
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.
Nature
387:49-55[CrossRef][Medline].
|
| 2.
|
Artavanis-Tsakonas, S.,
M. D. Rand, and R. J. Lake.
1999.
Notch signaling: cell fate control and signal integration in development.
Science
284:770-776[Abstract/Free Full Text].
|
| 3.
|
Aster, J. C.,
E. S. Robertson,
R. P. Hasserjian,
J. R. Turner,
E. Kieff, and J. Sklar.
1997.
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription.
J. Biol. Chem.
272:11336-11343[Abstract/Free Full Text].
|
| 4.
|
Bailey, A. M., and J. W. Posakony.
1995.
Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity.
Genes Dev.
9:2609-2622[Abstract/Free Full Text].
|
| 5.
|
Baudino, T. A.,
D. M. Kraichely,
S. C. Jefcoat, Jr.,
S. K. Winchester,
N. C. Partridge, and P. N. MacDonald.
1998.
Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription.
J. Biol. Chem.
273:16434-16441[Abstract/Free Full Text].
|
| 6.
|
Blaumueller, C. M.,
H. Qi,
P. Zagouras, and S. Artavanis-Tsakonas.
1997.
Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane.
Cell
90:281-291[CrossRef][Medline].
|
| 7.
|
Chan, Y.-M., and Y. N. Jan.
1998.
Roles for proteolysis and trafficking in Notch maturation and signal transduction.
Cell
94:423-426[CrossRef][Medline].
|
| 8.
|
Chen, J. D., and R. M. Evans.
1995.
A transcriptional co-repressor that interacts with nuclear hormone receptors.
Nature
377:454-457[CrossRef][Medline].
|
| 9.
|
Christensen, S.,
V. Kodoyianni,
M. Bosenberg,
L. Friedman, and J. Kimble.
1996.
lag-1, a gene required for lin-12 and glp-1 signaling in Caenorhabditis elegans, is homologous to human CBF1 and Drosophila Su(H).
Development
122:1373-1383[Abstract].
|
| 10.
|
Dahl, R.,
M. Kieslinger,
H. Beug, and M. J. Hayman.
1998.
Transformation of hematopoietic cells by the Ski oncoprotein involves repression of retinoic acid receptor signaling.
Proc. Natl. Acad. Sci. USA
95:11187-11192[Abstract/Free Full Text].
|
| 11.
|
Dahl, R.,
B. Wani, and M. J. Hayman.
1998.
The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42.
Oncogene
16:1579-1586[CrossRef][Medline].
|
| 12.
|
De Strooper, B.,
W. Annaert,
P. Cupers,
P. Saftig,
K. Craessaerts,
J. S. Mumm,
E. H. Schroeter,
V. Schrijvers,
M. S. Wolfe,
W. J. Ray,
A. Goate, and R. Kopan.
1999.
A presenilin-1-dependent -secretase-like protease mediates release of Notch intracellular domain.
Nature
398:518-522[CrossRef][Medline].
|
| 13.
|
Dou, S.,
X. Zeng,
P. Cortes,
H. Erdjument-Bromage,
P. Tempst,
T. Honjo, and L. D. Vales.
1994.
The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor.
Mol. Cell. Biol.
14:3310-3319[Abstract/Free Full Text].
|
| 14.
|
Ellisen, L. W.,
J. Bird,
D. C. West,
A. L. Soreng,
T. C. Reynolds,
S. D. Smith, and J. Sklar.
1991.
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.
Cell
66:649-661[CrossRef][Medline].
|
| 15.
|
Fortini, M. E., and S. Artavanis-Tsakonas.
1994.
The Suppressor of Hairless protein participates in Notch receptor signaling.
Cell
79:273-282[CrossRef][Medline].
|
| 16.
|
Fortini, M. E.,
I. Rebay,
L. A. Caron, and S. Artavanis-Tsakonas.
1993.
An activated Notch receptor blocks cell-fate commitment in the developing Drosophila eye.
Nature
365:555-557[CrossRef][Medline].
|
| 17.
|
Girard, L.,
Z. Hanna,
N. Beaulieu,
C. D. Hoemann,
C. Simard,
C. A. Kozak, and P. Jolicoeur.
1996.
Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis.
Genes Dev.
10:1930-1944[Abstract/Free Full Text].
|
| 18.
|
Greenwald, I.
1998.
LIN-12/Notch signaling: lessons from worms and flies.
Genes Dev.
12:1751-1762[Free Full Text].
|
| 19.
|
Hardwick, J. M.,
L. Tse,
N. Applegren,
J. Nicholas, and M. A. Veliuona.
1992.
The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.
J. Virol.
66:5500-5508[Abstract/Free Full Text].
|
| 20.
|
Hassig, C. A.,
T. C. Fleischer,
A. N. Billin,
S. L. Schreiber, and D. E. Ayer.
1997.
Histone deacetylase activity is required for full transcriptional repression by mSin3A.
Cell
89:341-347[CrossRef][Medline].
|
| 21.
|
Heinzel, T.,
R. M. Lavinsky,
T. M. Mullen,
M. Soderstrom,
C. D. Laherty,
J. Torchia,
W. M. Yang,
G. Brard,
S. D. Ngo,
J. R. Davie,
E. Seto,
R. N. Eisenman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1997.
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.
Nature
387:43-48[CrossRef][Medline].
|
| 22.
|
Hsieh, J. J.-D., and S. D. Hayward.
1995.
Masking of the CBF1/RBPJk transcriptional repression domain by Epstein-Barr virus EBNA2.
Science
268:560-563[Abstract/Free Full Text].
|
| 23.
|
Hsieh, J. J.-D.,
T. Henkel,
P. Salmon,
E. Robey,
M. G. Peterson, and S. D. Hayward.
1996.
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.
Mol. Cell. Biol.
16:952-959[Abstract].
|
| 24.
|
Hsieh, J. J.-D.,
D. E. Nofziger,
G. Weinmaster, and S. D. Hayward.
1997.
EBV immortalization: Notch2 interacts with CBF1 and blocks differentiation.
J. Virol.
71:1938-1945[Abstract].
|
| 25.
|
Hsieh, J. J.-D.,
S. Zhou,
L. Chen,
D. B. Young, and S. D. Hayward.
1999.
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex.
Proc. Natl. Acad. Sci. USA
96:23-28[Abstract/Free Full Text].
|
| 26.
|
Jarriault, S.,
C. Brou,
F. Logeat,
E. H. Schroeter,
R. Kopan, and A. Israel.
1995.
Signalling downstream of activated mammalian Notch.
Nature
377:355-358[CrossRef][Medline].
|
| 27.
|
Jhappan, C.,
D. Gallahan,
C. Stahle,
E. Chu,
G. H. Smith,
G. Merlino, and R. Callahan.
1992.
Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands.
Genes Dev.
6:345-355[Abstract/Free Full Text].
|
| 28.
|
Kao, H.-Y.,
P. Ordentlich,
N. Koyano-Nakagawa,
Z. Tang,
M. Downes,
C. R. Kintner,
R. M. Evans, and T. Kadesch.
1998.
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway.
Genes Dev.
12:2269-2277[Abstract/Free Full Text].
|
| 29.
|
Kimble, J., and P. Simpson.
1997.
The LIN-12/Notch signaling pathway and its regulation.
Annu. Rev. Cell Dev. Biol.
13:333-361[CrossRef][Medline].
|
| 30.
|
Kopan, R.,
J. S. Nye, and H. Weintraub.
1994.
The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD.
Development
120:2385-2396[Abstract/Free Full Text].
|
| 31.
|
Kopan, R.,
E. H. Schroeter,
H. Weintraub, and J. S. Nye.
1996.
Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.
Proc. Natl. Acad. Sci. USA
93:1683-1688[Abstract/Free Full Text].
|
| 32.
|
Kurooka, H.,
K. Kuroda, and T. Honjo.
1998.
Roles of the ankyrin repeats and C-terminal region of the mouse notch1 intracellular region.
Nucleic Acids Res.
26:5448-5455[Abstract/Free Full Text].
|
| 33.
|
Laherty, C. D.,
A. N. Billin,
R. M. Lavinsky,
G. S. Yochum,
A. C. Bush,
J.-M. Sun,
T.-M. Mullen,
J. R. Davie,
D. W. Rose,
C. K. Glass,
M. G. Rosenfeld,
D. E. Ayer, and R. N. Eisenman.
1998.
SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors.
Mol. Cell
2:33-42[CrossRef][Medline].
|
| 34.
|
Laherty, C. D.,
W. M. Yang,
J. M. Sun,
J. R. Davie,
E. Seto, and R. N. Eisenman.
1997.
Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression.
Cell
89:349-356[CrossRef][Medline].
|
| 35.
|
Lecourtois, M., and F. Schweisguth.
1998.
Indirect evidence for Delta-dependent intracellular processing of Notch in Drosophila embryos.
Curr. Biol.
8:771-774[CrossRef][Medline].
|
| 36.
|
Lecourtois, M., and F. Schweisguth.
1995.
The neurogenic Suppressor of Hairless DNA-binding protein mediates the transcriptional activation of the Enhancer of split complex genes triggered by Notch signaling.
Genes Dev.
9:2598-2608[Abstract/Free Full Text].
|
| 37.
|
Lieber, T.,
S. Kidd,
E. Alcamo,
V. Corbin, and M. W. Young.
1993.
Antineurogenic phenotypes induced by truncated Notch proteins indicate a role in signal transduction and may point to a novel function for Notch in nuclei.
Genes Dev.
7:1949-1965[Abstract/Free Full Text].
|
| 38.
|
Ling, P. D., and S. D. Hayward.
1995.
Contribution of conserved amino acids in mediating interaction between EBNA2 and CBF1/RBPJk.
J. Virol.
69:1944-1950[Abstract].
|
| 39.
|
Ling, P. D.,
J. J.-D. Hsieh,
I. K. Ruf,
D. R. Rawlins, and S. D. Hayward.
1994.
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
J. Virol.
68:5375-5383[Abstract/Free Full Text].
|
| 40.
|
Ling, P. D.,
J. J. Ryon, and S. D. Hayward.
1993.
EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.
J. Virol.
67:2990-3003[Abstract/Free Full Text].
|
| 41.
|
Logeat, F.,
C. Bessia,
C. Brou,
O. LeBail,
S. Jarriault,
N. G. Seidah, and A. Israel.
1998.
The Notch1 receptor is cleaved constitutively by a furin-like convertase.
Proc. Natl. Acad. Sci. USA
95:8108-8112[Abstract/Free Full Text].
|
| 42.
|
Nagy, L.,
H. Y. Kao,
D. Chakravarti,
R. J. Lin,
C. A. Hassig,
D. E. Ayer,
S. L. Schreiber, and R. M. Evans.
1997.
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.
Cell
89:373-380[CrossRef][Medline].
|
| 43.
|
Nofziger, D.,
A. Miyamoto,
K. M. Lyons, and G. Weinmaster.
1999.
Notch signaling imposes two distinct blocks in the differentiation of C2C12 myoblasts.
Development
126:1689-1702[Abstract].
|
| 44.
|
Nomura, T.,
M. M. Khan,
S. C. Kaul,
H.-D. Dong,
R. Wadhwa,
C. Colmenares,
I. Kohno, and S. Ishii.
1999.
Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor.
Genes Dev.
13:412-423[Abstract/Free Full Text].
|
| 45.
|
Ohtsuka, T.,
M. Ishibashi,
G. Gradwohl,
S. Nakanishi,
F. Guillemot, and R. Kageyama.
1999.
Hes1 and Hes5 as Notch effectors in mammalian neuronal differentiation.
EMBO J.
18:2196-2207[CrossRef][Medline].
|
| 46.
|
Olave, I.,
D. Reinberg, and L. D. Vales.
1998.
The mammalian transcriptional repressor RBP (CBF1) targets TFIID and TFIIA to prevent activated transcription.
Genes Dev.
12:1621-1637[Abstract/Free Full Text].
|
| 47.
|
Pear, W. S.,
J. C. Aster,
M. L. Scott,
R. P. Hasserjian,
B. Soffer,
J. Sklar, and D. Baltimore.
1996.
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.
J. Exp. Med.
183:2283-2291[Abstract/Free Full Text].
|
| 48.
|
Ray, W. J.,
M. Yao,
P. Nowotny,
J. Mumm,
W. Zhang,
J. Y. Wu,
R. Kopan, and A. M. Goate.
1999.
Evidence for a physical interaction between presenilin and Notch.
Proc. Natl. Acad. Sci. USA
96:3263-3268[Abstract/Free Full Text].
|
| 49.
|
Rebay, I.,
R. G. Fehon, and S. Artavanis-Tsakonas.
1993.
Specific truncations of Drosophila Notch define dominant activated and dominant negative forms of the receptor.
Cell
74:319-329[CrossRef][Medline].
|
| 50.
|
Roehl, H.,
M. Bosenberg,
R. Blelloch, and J. Kimble.
1996.
Roles of the RAM and ANK domains in signaling by the C. elegans GLP-1 receptor.
EMBO J.
15:7002-7012[Medline].
|
| 51.
|
Roehl, H., and J. Kimble.
1993.
Control of cell fate in C. elegans by a GLP-1 peptide consisting primarily of ankyrin repeats.
Nature
364:632-635[CrossRef][Medline].
|
| 52.
|
Rohn, J. L.,
A. S. Lauring,
M. L. Linenberger, and J. Overbaugh.
1996.
Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.
J. Virol.
70:8071-8080[Abstract].
|
| 53.
|
Schroeter, E. H.,
J. A. Kisslinger, and R. Kopan.
1998.
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain.
Nature
393:382-386[CrossRef][Medline].
|
| 54.
|
Shawber, C.,
D. Nofziger,
J. J.-D. Hsieh,
C. Lindsell,
O. Bogler,
S. D. Hayward, and G. Weinmaster.
1996.
Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway.
Development
122:3765-3773[Abstract].
|
| 55.
|
Struhl, G., and A. Adachi.
1998.
Nuclear access and action of notch in vivo.
Cell
93:649-660[CrossRef][Medline].
|
| 56.
|
Struhl, G.,
K. Fitzgerald, and I. Greenwald.
1993.
Intrinsic activity of the Lin-12 and Notch intracellular domains in vivo.
Cell
74:331-345[CrossRef][Medline].
|
| 57.
|
Struhl, G., and I. Greenwald.
1999.
Presenilin is required for activity and nuclear access of Notch in Drosophila.
Nature
398:522-525[CrossRef][Medline].
|
| 58.
|
Tun, T.,
Y. Hamaguchi,
N. Matsunami,
T. Furukawa,
T. Honjo, and M. Kawaichi.
1994.
Recognition sequence of a highly conserved DNA binding protein RBP-J kappa.
Nucleic Acids Res.
22:965-971[Abstract/Free Full Text].
|
| 59.
|
Weinmaster, G.
1997.
Review: the ins and outs of Notch signaling.
Mol. Cell. Neurosci.
9:91-102[CrossRef][Medline].
|
| 60.
|
Ye, Y.,
N. Lukinova, and M. E. Fortini.
1999.
Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants.
Nature
398:525-529[CrossRef][Medline].
|
| 61.
|
Zhang, Y.,
R. Iratni,
H. Erdjument-Bromage,
P. Tempst, and D. Reinberg.
1997.
Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex.
Cell
89:357-364[CrossRef][Medline].
|
| 62.
|
Zhang, Y.,
Z.-W. Sun,
R. Iratni,
H. Erdjument-Bromage,
P. Tempst,
M. Hampsey, and D. Reinberg.
1998.
SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex.
Mol. Cell
1:1021-1031[CrossRef][Medline].
|
| 63.
|
Zhou, S.,
M. Fujimuro,
J. J.-D. Hsieh,
L. Chen, and S. D. Hayward.
2000.
A role for SKIP in EBNA2 activation of CBF1-repressed promoters.
J. Virol.
74:1939-1947[Abstract/Free Full Text].
|
Molecular and Cellular Biology, April 2000, p. 2400-2410, Vol. 20, No. 7
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Huang, L., Chi, J., Berry, F. B., Footz, T. K., Sharp, M. W., Walter, M. A.
(2008). Human p32 Is a Novel FOXC1-Interacting Protein That Regulates FOXC1 Transcriptional Activity in Ocular Cells. IOVS
49: 5243-5249
[Abstract]
[Full Text]
-
del Alamo, D., Mlodzik, M.
(2008). Self-modulation of Notch signaling during ommatidial development via the Roughened eye transcriptional repressor. Development
135: 2895-2904
[Abstract]
[Full Text]
-
Friedmann, D. R., Wilson, J. J., Kovall, R. A.
(2008). RAM-induced Allostery Facilitates Assembly of a Notch Pathway Active Transcription Complex. J. Biol. Chem.
283: 14781-14791
[Abstract]
[Full Text]
-
Sakamoto, K., Tamamura, Y., Katsube, K.-i., Yamaguchi, A.
(2008). Zfp64 participates in Notch signaling and regulates differentiation in mesenchymal cells. J. Cell Sci.
121: 1613-1623
[Abstract]
[Full Text]
-
Michie, A. M., Chan, A. C., Ciofani, M., Carleton, M., Lefebvre, J. M., He, Y., Allman, D. M., Wiest, D. L., Zuniga-Pflucker, J. C., Izon, D. J.
(2007). Constitutive Notch signalling promotes CD4 CD8 thymocyte differentiation in the absence of the pre-TCR complex, by mimicking pre-TCR signals. Int Immunol
19: 1421-1430
[Abstract]
[Full Text]
-
Fiuza, U.-M., Arias, A. M.
(2007). Cell and molecular biology of Notch. J Endocrinol
194: 459-474
[Abstract]
[Full Text]
-
Niessen, K., Karsan, A.
(2007). Notch signaling in the developing cardiovascular system. Am. J. Physiol. Cell Physiol.
293: C1-C11
[Abstract]
[Full Text]
-
Curry, C. L., Reed, L. L., Broude, E., Golde, T. E., Miele, L., Foreman, K. E.
(2007). Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-{kappa}B signaling. Molecular Cancer Therapeutics
6: 1983-1992
[Abstract]
[Full Text]
-
Ma, X., Renda, M. J., Wang, L., Cheng, E.-c., Niu, C., Morris, S. W., Chi, A. S., Krause, D. S.
(2007). Rbm15 Modulates Notch-Induced Transcriptional Activation and Affects Myeloid Differentiation. Mol. Cell. Biol.
27: 3056-3064
[Abstract]
[Full Text]
-
Ehebauer, M., Hayward, P., Martinez-Arias, A.
(2006). Notch Signaling Pathway. Sci Signal
2006: cm7-cm7
[Abstract]
[Full Text]
-
Carroll, K. D., Bu, W., Palmeri, D., Spadavecchia, S., Lynch, S. J., Marras, S. A. E., Tyagi, S., Lukac, D. M.
(2006). Kaposi's Sarcoma-Associated Herpesvirus Lytic Switch Protein Stimulates DNA Binding of RBP-Jk/CSL To Activate the Notch Pathway. J. Virol.
80: 9697-9709
[Abstract]
[Full Text]
-
Nagel, A. C., Krejci, A., Tenin, G., Bravo-Patino, A., Bray, S., Maier, D., Preiss, A.
(2005). Hairless-Mediated Repression of Notch Target Genes Requires the Combined Activity of Groucho and CtBP Corepressors. Mol. Cell. Biol.
25: 10433-10441
[Abstract]
[Full Text]
-
Katic, I., Vallier, L. G., Greenwald, I.
(2005). New Positive Regulators of lin-12 Activity in Caenorhabditis elegans Include the BRE-5/Brainiac Glycosphingolipid Biosynthesis Enzyme. Genetics
171: 1605-1615
[Abstract]
[Full Text]
-
Maier, S., Santak, M., Mantik, A., Grabusic, K., Kremmer, E., Hammerschmidt, W., Kempkes, B.
(2005). A Somatic Knockout of CBF1 in a Human B-Cell Line Reveals that Induction of CD21 and CCR7 by EBNA-2 Is Strictly CBF1 Dependent and that Downregulation of Immunoglobulin M Is Partially CBF1 Independent. J. Virol.
79: 8784-8792
[Abstract]
[Full Text]
-
Wu, J., Iwata, F., Grass, J. A., Osborne, C. S., Elnitski, L., Fraser, P., Ohneda, O., Yamamoto, M., Bresnick, E. H.
(2005). Molecular Determinants of NOTCH4 Transcription in Vascular Endothelium. Mol. Cell. Biol.
25: 1458-1474
[Abstract]
[Full Text]
-
Chen, H., Huang, J., Wu, F. Y., Liao, G., Hutt-Fletcher, L., Hayward, S. D.
(2005). Regulation of Expression of the Epstein-Barr Virus BamHI-A Rightward Transcripts. J. Virol.
79: 1724-1733
[Abstract]
[Full Text]
-
Lee, J. M., Lee, K.-H., Farrell, C. J., Ling, P. D., Kempkes, B., Park, J. H., Hayward, S. D.
(2004). EBNA2 Is Required for Protection of Latently Epstein-Barr Virus-Infected B Cells against Specific Apoptotic Stimuli. J. Virol.
78: 12694-12697
[Abstract]
[Full Text]
-
Laduron, S., Deplus, R., Zhou, S., Kholmanskikh, O., Godelaine, D., De Smet, C., Hayward, S. D., Fuks, F., Boon, T., De Plaen, E.
(2004). MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res
32: 4340-4350
[Abstract]
[Full Text]
-
Tanimizu, N., Miyajima, A.
(2004). Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J. Cell Sci.
117: 3165-3174
[Abstract]
[Full Text]
-
Ross, D. A., Rao, P. K., Kadesch, T.
(2004). Dual Roles for the Notch Target Gene Hes-1 in the Differentiation of 3T3-L1 Preadipocytes. Mol. Cell. Biol.
24: 3505-3513
[Abstract]
[Full Text]
-
Trifonova, R., Small, D., Kacer, D., Kovalenko, D., Kolev, V., Mandinova, A., Soldi, R., Liaw, L., Prudovsky, I., Maciag, T.
(2004). The non-transmembrane form of Delta1 but not of jagged1 Induces normal migratory behavior accompanied by FGF receptor 1-dependent transformation. J. Biol. Chem.
0: 300564200-1
[Abstract]
-
Chu, J., Bresnick, E. H.
(2004). Evidence That C Promoter-binding Factor 1 Binding Is Required for Notch-1-mediated Repression of Activator Protein-1. J. Biol. Chem.
279: 12337-12345
[Abstract]
[Full Text]
-
Dahlqvist, C., Blokzijl, A., Chapman, G., Falk, A., Dannaeus, K., Ibanez, C. F., Lendahl, U.
(2003). Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development
130: 6089-6099
[Abstract]
[Full Text]
-
Sciaudone, M., Gazzerro, E., Priest, L., Delany, A. M., Canalis, E.
(2003). Notch 1 Impairs Osteoblastic Cell Differentiation. Endocrinology
144: 5631-5639
[Abstract]
[Full Text]
-
Yeh, T.-S., Lin, Y.-M., Hsieh, R.-H., Tseng, M.-J.
(2003). Association of Transcription Factor YY1 with the High Molecular Weight Notch Complex Suppresses the Transactivation Activity of Notch. J. Biol. Chem.
278: 41963-41969
[Abstract]
[Full Text]
-
Alazard, N., Gruffat, H., Hiriart, E., Sergeant, A., Manet, E.
(2003). Differential Hyperacetylation of Histones H3 and H4 upon Promoter-Specific Recruitment of EBNA2 in Epstein-Barr Virus Chromatin. J. Virol.
77: 8166-8172
[Abstract]
[Full Text]
-
Oakley, F., Mann, J., Ruddell, R. G., Pickford, J., Weinmaster, G., Mann, D. A.
(2003). Basal Expression of I{kappa}B{alpha} Is Controlled by the Mammalian Transcriptional Repressor RBP-J (CBF1) and Its Activator Notch1. J. Biol. Chem.
278: 24359-24370
[Abstract]
[Full Text]
-
Kostrouchova, M., Kostrouch, Z., Saudek, V., Piatigorsky, J., Rall, J. E.
(2003). BIR-1, a Caenorhabditis elegans homologue of Survivin, regulates transcription and development. Proc. Natl. Acad. Sci. USA
100: 5240-5245
[Abstract]
[Full Text]
-
Barry, J. B., Leong, G. M., Church, W. B., Issa, L. L., Eisman, J. A., Gardiner, E. M.
(2003). Interactions of SKIP/NCoA-62, TFIIB, and Retinoid X Receptor with Vitamin D Receptor Helix H10 Residues. J. Biol. Chem.
278: 8224-8228
[Abstract]
[Full Text]
-
Wu, F. Y., Chen, H., Wang, S. E., apRhys, C. M. J., Liao, G., Fujimuro, M., Farrell, C. J., Huang, J., Hayward, S. D., Hayward, G. S.
(2002). CCAAT/Enhancer Binding Protein {alpha} Interacts with ZTA and Mediates ZTA-Induced p21CIP-1 Accumulation and G1 Cell Cycle Arrest during the Epstein-Barr Virus Lytic Cycle. J. Virol.
77: 1481-1500
[Abstract]
[Full Text]
-
Prathapam, T., Kuhne, C., Banks, L.
(2002). Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res
30: 5261-5268
[Abstract]
[Full Text]
-
Jarriault, S., Greenwald, I.
(2002). Suppressors of the egg-laying defective phenotype of sel-12 presenilin mutants implicate the CoREST corepressor complex in LIN-12/Notch signaling in C. elegans. Genes Dev.
16: 2713-2728
[Abstract]
[Full Text]
-
Lee, J. M., Lee, K.-H., Weidner, M., Osborne, B. A., Hayward, S. D.
(2002). Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis. Proc. Natl. Acad. Sci. USA
99: 11878-11883
[Abstract]
[Full Text]
-
Wu, F. Y., Tang, Q.-Q., Chen, H., ApRhys, C., Farrell, C., Chen, J., Fujimuro, M., Lane, M. D., Hayward, G. S.
(2002). Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. Proc. Natl. Acad. Sci. USA
99: 10683-10688
[Abstract]
[Full Text]
-
Wardell, S. E., Boonyaratanakornkit, V., Adelman, J. S., Aronheim, A., Edwards, D. P.
(2002). Jun Dimerization Protein 2 Functions as a Progesterone Receptor N-Terminal Domain Coactivator. Mol. Cell. Biol.
22: 5451-5466
[Abstract]
[Full Text]
-
Kostrouchova, M., Housa, D., Kostrouch, Z., Saudek, V., Rall, J. E.
(2002). SKIP is an indispensable factor for Caenorhabditis elegans development. Proc. Natl. Acad. Sci. USA
99: 9254-9259
[Abstract]
[Full Text]
-
Gordadze, A. V., Poston, D., Ling, P. D.
(2002). The EBNA2 Polyproline Region Is Dispensable for Epstein-Barr Virus-Mediated Immortalization Maintenance. J. Virol.
76: 7349-7355
[Abstract]
[Full Text]
-
Fryer, C. J., Lamar, E., Turbachova, I., Kintner, C., Jones, K. A.
(2002). Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex. Genes Dev.
16: 1397-1411
[Abstract]
[Full Text]
-
Roncarati, R., Sestan, N., Scheinfeld, M. H., Berechid, B. E., Lopez, P. A., Meucci, O., McGlade, J. C., Rakic, P., D'Adamio, L.
(2002). The gamma -secretase-generated intracellular domain of beta -amyloid precursor protein binds Numb and inhibits Notch signaling. Proc. Natl. Acad. Sci. USA
99: 7102-7107
[Abstract]
[Full Text]
-
Sriuranpong, V., Borges, M. W., Strock, C. L., Nakakura, E. K., Watkins, D. N., Blaumueller, C. M., Nelkin, B. D., Ball, D. W.
(2002). Notch Signaling Induces Rapid Degradation of Achaete-Scute Homolog 1. Mol. Cell. Biol.
22: 3129-3139
[Abstract]
[Full Text]
-
Chu, J., Jeffries, S., Norton, J. E., Capobianco, A. J., Bresnick, E. H.
(2002). Repression of Activator Protein-1-mediated Transcriptional Activation by the Notch-1 Intracellular Domain. J. Biol. Chem.
277: 7587-7597
[Abstract]
[Full Text]
-
Fennewald, S. M., Aronson, J. F., Zhang, L., Herzog, N. K.
(2002). Alterations in NF-{kappa}B and RBP-J{kappa} by Arenavirus Infection of Macrophages In Vitro and In Vivo. J. Virol.
76: 1154-1162
[Abstract]
[Full Text]
-
Ross, D. A., Kadesch, T.
(2001). The Notch Intracellular Domain Can Function as a Coactivator for LEF-1. Mol. Cell. Biol.
21: 7537-7544
[Abstract]
[Full Text]
-
Zhou, S., Hayward, S. D.
(2001). Nuclear Localization of CBF1 Is Regulated by Interactions with the SMRT Corepressor Complex. Mol. Cell. Biol.
21: 6222-6232
[Abstract]
[Full Text]
-
Ronchini, C., Capobianco, A. J.
(2001). Induction of Cyclin D1 Transcription and CDK2 Activity by Notchic: Implication for Cell Cycle Disruption in Transformation by Notchic. Mol. Cell. Biol.
21: 5925-5934
[Abstract]
[Full Text]
-
Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L., Hamamori, Y.
(2001). HERP, a New Primary Target of Notch Regulated by Ligand Binding. Mol. Cell. Biol.
21: 6071-6079
[Abstract]
[Full Text]
-
Prathapam, T., Kuhne, C., Hayman, M., Banks, L.
(2001). Ski interacts with the evolutionarily conserved SNW domain of Skip. Nucleic Acids Res
29: 3469-3476
[Abstract]
[Full Text]
-
Lamar, E., Deblandre, G., Wettstein, D., Gawantka, V., Pollet, N., Niehrs, C., Kintner, C.
(2001). Nrarp is a novel intracellular component of the Notch signaling pathway. Genes Dev.
15: 1885-1899
[Abstract]
[Full Text]
-
Allman, D., Karnell, F. G., Punt, J. A., Bakkour, S., Xu, L., Myung, P., Koretzky, G. A., Pui, J. C., Aster, J. C., Pear, W. S.
(2001). Separation of Notch1 Promoted Lineage Commitment and Expansion/Transformation in Developing T Cells. JEM
194: 99-106
[Abstract]
[Full Text]
-
Wang, J., Shelly, L., Miele, L., Boykins, R., Norcross, M. A., Guan, E.
(2001). Human Notch-1 Inhibits NF-{{kappa}}B Activity in the Nucleus Through a Direct Interaction Involving a Novel Domain. J. Immunol.
167: 289-295
[Abstract]
[Full Text]
-
Staal, F. J.T., Weerkamp, F., Langerak, A. W., Hendriks, R. W., Clevers, H. C.
(2001). Transcriptional Control of T Lymphocyte Differentiation. Stem Cells
19: 165-179
[Abstract]
[Full Text]
-
Zhang, J., Chen, H., Weinmaster, G., Hayward, S. D.
(2001). Epstein-Barr Virus BamHI-A Rightward Transcript-Encoded RPMS Protein Interacts with the CBF1-Associated Corepressor CIR To Negatively Regulate the Activity of EBNA2 and NotchIC. J. Virol.
75: 2946-2956
[Abstract]
[Full Text]
-
Aster, J. C., Xu, L., Karnell, F. G., Patriub, V., Pui, J. C., Pear, W. S.
(2000). Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of T-Cell Leukemia by Notch1. Mol. Cell. Biol.
20: 7505-7515
[Abstract]
[Full Text]
-
Nicholas, J
(2000). Evolutionary aspects of oncogenic herpesviruses. Mol. Pathol.
53: 222-237
[Abstract]
[Full Text]
-
Doyle, T. G., Wen, C., Greenwald, I.
(2000). SEL-8, a nuclear protein required for LIN-12 and GLP-1 signaling in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA
97: 7877-7881
[Abstract]
[Full Text]
-
Leong, G. M., Subramaniam, N., Figueroa, J., Flanagan, J. L., Hayman, M. J., Eisman, J. A., Kouzmenko, A. P.
(2001). Ski-interacting Protein Interacts with Smad Proteins to Augment Transforming Growth Factor-beta -dependent Transcription. J. Biol. Chem.
276: 18243-18248
[Abstract]
[Full Text]
-
Yamamoto, N., Yamamoto, S.-i., Inagaki, F., Kawaichi, M., Fukamizu, A., Kishi, N., Matsuno, K., Nakamura, K., Weinmaster, G., Okano, H., Nakafuku, M.
(2001). Role of Deltex-1 as a Transcriptional Regulator Downstream of the Notch Receptor. J. Biol. Chem.
276: 45031-45040
[Abstract]
[Full Text]